Silver Book Fact

Tools to Prevent Secondary Osteoporosis Fractures are Not Being Used

Fact image

Hansen D, Bazell C, Pelizzari P, Pyenson B. Medicare Cost of Osteoporotic Fractures. Milliman Research Report. 2019; https://static1.squarespace.com/static/5c0860aff793924efe2230f3/t/5d76b949deb7e9086ee3d7dd/1568061771769/Medicare+Cost+of+Osteoporotic+Fractures+20190827.pdf

Reference

Title
Medicare Cost of Osteoporotic Fractures
Publication
Milliman Research Report
Publication Date
2019
Authors
Hansen D, Bazell C, Pelizzari P, Pyenson B
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value
  • Economic Value
  • Future Value

Related Facts

  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.